Pfizer Limited (PFIZER.NS) Stock Analysis & Winston Score

Pfizer Limited (listed in India) is the Indian subsidiary of Pfizer Inc., one of the largest pharmaceutical companies in the world. It makes and sells prescription medicines, vaccines, and consumer health products to hospitals, doctors, and patients across India. Key products include medicines for pain, inflammation, infections, and hospital care, sold under well-known brand names like Corex and Dolonex.

The company earns money primarily by selling branded medicines to distributors, hospitals, and pharmacies across India. Being part of the global Pfizer network gives it access to research, technology, and established drug brands that smaller local competitors cannot easily replicate — this is its main competitive advantage. However, the business faces real risks from India's drug price control regulations, which cap how much companies can charge for essential medicines, limiting how much revenue and profit the company can grow over time.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+6.3% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-39.6% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

66.9%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

$31.3B cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Pfizer Limited is growing revenue at 6% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

−0.0% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 45.8M (2022) → 45.7M (2026)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

50.4%

Healthy — 50.4% gross margin

Operating Margin

35.1%

Excellent — 35.1% operating margin

ROCE

5.2%

Weak — 5.2% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+10.2%

Steady sales growth (10.2% YoY)

EPS YoY

+31.2%

Earnings growing fast (31.2% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

70%

Modest — 70% of profit becomes cash

FCF Margin

23.5%

Converts sales into free cash efficiently (23.5%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.01

Conservative — low debt load (0.01)

Interest Cover

100.26x

Comfortably covers interest (100.3x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

24.2x

Growth-priced — P/E 24.2

P/E above the market average. People are paying up for expected growth.

P/E vs Forward

-0.9

SLOWING

Earnings expected to fall — forward P/E higher than today

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield

3.61%

Moderate income — 3.61% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend Growth

+186.4%

Dividend growing fast (186.4% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial